JP2020525765A - Ｉｌ−１０、ｓ１００ｂおよびｈ−ｆａｂｐマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用 - Google Patents

Ｉｌ−１０、ｓ１００ｂおよびｈ−ｆａｂｐマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用 Download PDF

Info

Publication number
JP2020525765A
JP2020525765A JP2019569961A JP2019569961A JP2020525765A JP 2020525765 A JP2020525765 A JP 2020525765A JP 2019569961 A JP2019569961 A JP 2019569961A JP 2019569961 A JP2019569961 A JP 2019569961A JP 2020525765 A JP2020525765 A JP 2020525765A
Authority
JP
Japan
Prior art keywords
tbi
markers
protein
fabp
mtbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525765A5 (enExample
Inventor
サンシェ ジャン−シャルル
サンシェ ジャン−シャルル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneva, University of
Original Assignee
Geneva, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneva, University of filed Critical Geneva, University of
Publication of JP2020525765A publication Critical patent/JP2020525765A/ja
Publication of JP2020525765A5 publication Critical patent/JP2020525765A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019569961A 2017-06-15 2018-06-07 Ｉｌ−１０、ｓ１００ｂおよびｈ−ｆａｂｐマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用 Pending JP2020525765A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17001015 2017-06-15
EP17001015.1 2017-06-15
PCT/EP2018/065090 WO2018228927A1 (en) 2017-06-15 2018-06-07 Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury

Publications (2)

Publication Number Publication Date
JP2020525765A true JP2020525765A (ja) 2020-08-27
JP2020525765A5 JP2020525765A5 (enExample) 2021-07-26

Family

ID=59091305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019569961A Pending JP2020525765A (ja) 2017-06-15 2018-06-07 Ｉｌ−１０、ｓ１００ｂおよびｈ−ｆａｂｐマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用

Country Status (6)

Country Link
US (1) US20200174015A1 (enExample)
EP (1) EP3639034A1 (enExample)
JP (1) JP2020525765A (enExample)
CN (1) CN110770586A (enExample)
AU (1) AU2018283348A1 (enExample)
WO (1) WO2018228927A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157206A1 (en) * 2019-01-31 2020-08-06 University Of Geneva Prospective markers in traumatic brain injury (tbi)
CN115170540B (zh) * 2022-07-26 2025-07-11 浙江工业大学 一种基于多模态影像特征融合的轻度创伤性脑损伤分类方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
WO2016055148A2 (en) * 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
US20170023591A1 (en) * 2014-04-07 2017-01-26 Iron Horse Diagnostics, Inc. Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
WO2016055148A2 (en) * 2014-10-06 2016-04-14 Université De Genève Markers and their use in brain injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DASH, P.K. ET AL.: "Biomarkers for the Diagnosis, Prognosis, and Evaluation of Treatment Efficacy for Traumatic Brain In", NEUROTHERAPEUTICS, vol. 7, JPN6022012426, 2010, pages 100 - 114, XP026824397, ISSN: 0004904286 *
SINGH,K. ET AL.: "Longitudinal changes in the DTI measures, anti-GFAP expression and levels of serum inflammatory cyto", EXPERIMENTAL NEUROLOGY, vol. 275, JPN6022012424, 2016, pages 427 - 435, ISSN: 0004904287 *

Also Published As

Publication number Publication date
US20200174015A1 (en) 2020-06-04
AU2018283348A1 (en) 2020-01-02
EP3639034A1 (en) 2020-04-22
WO2018228927A1 (en) 2018-12-20
CN110770586A (zh) 2020-02-07

Similar Documents

Publication Publication Date Title
JP2020042046A (ja) マーカー群および該マーカー群の脳損傷における使用
Mahan et al. Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for positive computed tomography of the head in trauma subjects
Ingebrigtsen et al. The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study
CA2263063C (en) Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US20170023591A1 (en) Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
Whistler et al. Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome
US20130045542A1 (en) New formulations for diagnosis of alzheimer's disease
US20050136496A1 (en) Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
US12422442B2 (en) Markers and their use in brain injury
CN108431608B (zh) 用于诊断或预后阿尔茨海默病或用于诊断帕金森病的乳铁蛋白
Zhou et al. Diagnostic and Predictive Value of Novel inflammatory markers of the severity of Acute traumatic spinal cord Injury: a retrospective study
EP2816353A1 (en) A method for detecting risk of alzheimer's disease
Aydın et al. Diagnostic value of serum glial fibrillary acidic protein and S100B serum levels in emergency medicine patients with traumatic versus nontraumatic intracerebral hemorrhage
JP2020525765A (ja) Ｉｌ−１０、ｓ１００ｂおよびｈ−ｆａｂｐマーカー群ならびに該マーカー群の外傷性脳損傷の検出における使用
US20110236917A1 (en) Diagnosis of Alzheimer's Disease
EP3918336A1 (en) Prospective markers in traumatic brain injury (tbi)
Delefortrie et al. Evaluation of the Roche® Elecsys and the Diasorin® Liaison S100 kits in the management of mild head injury in the emergency room
EP3545310B1 (en) Gfap accumulating in stroke
US20180120333A1 (en) Diagnostic markers of cognitive impairments, kits and uses thereof
CN114250288B (zh) Dna甲基化特征和前脉冲抑制特征在精神分裂症诊断中的应用
Çelikel et al. Evaluation of NSE and GFAP level and hemorrhage volume in terms of prognosis in head trauma: A prospective controlled study.
GALHOM et al. Serum S100 Protein as a Predictor of Long Term Outcome in Mild and Moderate Traumatic Brain Injury
Brennan Utility Of Plasma Biomarkers In The Validation Of Reported Loc & Pta For Gcs 13-15 Patients: A Track-Tbi Pilot Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210602

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210602

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221025